{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:10:06Z","timestamp":1780416606328,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202201011359"],"award-info":[{"award-number":["202201011359"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012398"],"award-info":[{"award-number":["2022A1515012398"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071344"],"award-info":[{"award-number":["82071344"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101418"],"award-info":[{"award-number":["82101418"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.107008","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:21:12Z","timestamp":1768461672000},"page":"107008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Elevated serum complement shows promise as a potential clinically practical biomarker for disease activity in myelin oligodendrocyte glycoprotein antibody-associated disorders"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-4628","authenticated-orcid":false,"given":"Yiying","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Fabis-Pedrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-012X","authenticated-orcid":false,"given":"Xiaonan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107008_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107008_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107008_bib0002","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/13524585221150743","article-title":"Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"29","author":"Chia","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107008_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1320094","article-title":"Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder","volume":"15","author":"Cho","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107008_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107008_bib0007","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12264-019-00375-8","article-title":"Myelin oligodendrocyte glycoprotein-IgG contributes to oligodendrocytopathy in the presence of complement, distinct from astrocytopathy induced by AQP4-IgG","volume":"35","author":"Fang","year":"2019","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.msard.2026.107008_bib0008","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2026.107008_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200293","article-title":"Different complement activation patterns following C5 cleavage in MOGAD and AQP4-IgG+NMOSD","volume":"11","author":"Kaneko","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107008_bib0011","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement activation is a prominent feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107008_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12014-020-09281-y","article-title":"Proteomic analysis of human synovial fluid reveals potential diagnostic biomarkers for ankylosing spondylitis","volume":"17","author":"Lee","year":"2020","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.msard.2026.107008_bib0026","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200059","article-title":"More efficient complement activation by anti-aquaporin-4 compared with anti-myelin oligodendrocyte glycoprotein antibodies","volume":"10","author":"Lerch","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107008_bib0013","article-title":"Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107008_bib0016","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107008_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577699","article-title":"C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD","volume":"360","author":"Pache","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107008_bib0028","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2018.06.001","article-title":"Complement analysis in the era of targeted therapeutics","volume":"102","author":"Prohaszka","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.msard.2026.107008_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","article-title":"Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica","volume":"126","author":"Ratelade","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2026.107008_bib0021","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/1352458515571446","article-title":"Role of membrane complement regulators in neuromyelitis optica","volume":"21","author":"Saadoun","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107008_bib0009","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/acn3.712","article-title":"Brain histopathological study and prognosis in MOG antibody-associated demyelinating pseudotumor","volume":"6","author":"Shu","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107008_bib0020","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107008_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1209749","article-title":"Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders","volume":"14","author":"Takai","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107008_bib0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cca.2016.12.017","article-title":"Complement in autoimmune diseases","volume":"465","author":"Vignesh","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.msard.2026.107008_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200401","article-title":"Complement activation profiles predict clinical outcomes in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"12","author":"Villacieros-\u00c1lvarez","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107008_bib0025","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76640","article-title":"Cd59 and inflammation regulate Schwann cell development","volume":"11","author":"Wiltbank","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.msard.2026.107008_bib0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107008_bib0003","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00415-021-10749-6","article-title":"Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder","volume":"269","author":"Xie","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107008_bib0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40478-017-0462-4","article-title":"Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G","volume":"5","author":"Yao","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.msard.2026.107008_bib0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40478-017-0417-9","article-title":"Marked central nervous system pathology in CD59 knockout rats following passive transfer of neuromyelitis optica immunoglobulin G","volume":"5","author":"Yao","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.msard.2026.107008_bib0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2014.02.011","article-title":"Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59","volume":"53","author":"Zhang","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2026.107008_bib0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fneur.2019.00415","article-title":"Seizure and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis in a retrospective cohort of Chinese patients","volume":"10","author":"Zhong","year":"2019","journal-title":"Front. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:50:38Z","timestamp":1780415438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"alternative-id":["S2211034826000441"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107008","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated serum complement shows promise as a potential clinically practical biomarker for disease activity in myelin oligodendrocyte glycoprotein antibody-associated disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107008"}}